First person – Andrea R. López-Pastor and Jorge Infante-Menéndez

ABSTRACT First Person is a series of interviews with the first authors of a selection of papers published in Disease Models & Mechanisms, helping early-career researchers promote themselves alongside their papers. Andrea R. López-Pastor and Jorge Infante-Menéndez are co-first authors on ‘ Concerted regulation of non-alcoholic fatty liver disease progression by microRNAs in apolipoprotein E-deficient mice’, published in DMM. Andrea is a PhD student in the lab of Óscar Escribano and Almudena Gómez-Hernández at Complutense University of Madrid, Madrid, Spain, investigating molecular mechanisms by which microRNAs are involved in the progression of non-alcoholic fatty liver disease. Jorge is a research assistant in the same lab, investigating translational approaches to microRNA dysregulation in non-alcoholic fatty liver disease progression.

Download Full-text

Non-alcoholic fatty liver disease progression and current research

Asian Pacific Journal of Health Sciences ◽

10.21276/apjhs.2019.6.1.26 ◽

2019 ◽

Vol 6 (1) ◽

pp. 189-198

Author(s):

Smriti Narayan ◽

Sonu Kumar Gupta ◽

Priyanka Singh ◽

Villayat Ali ◽

Malkhey Verma

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Disease Progression ◽

Fatty Liver Disease ◽

Alcoholic Fatty Liver ◽

Liver Disease Progression ◽

Alcoholic Fatty Liver Disease

Download Full-text

A Role for Gut Microbiome Fermentative Pathways in Fatty Liver Disease Progression

Journal of Clinical Medicine ◽

10.3390/jcm9051369 ◽

2020 ◽

Vol 9 (5) ◽

pp. 1369 ◽

Cited By ~ 1

Author(s):

Paula Iruzubieta ◽

Juan M. Medina ◽

Raúl Fernández-López ◽

Javier Crespo ◽

Fernando de la Cruz

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Disease Progression ◽

Gut Microbiome ◽

Fatty Liver Disease ◽

Molecular Mechanisms ◽

Alcohol Fermentation ◽

Alcoholic Fatty Liver ◽

Liver Disease Progression ◽

The Impact

Non-alcoholic fatty liver disease (NAFLD) is a multifactorial disease in which environmental and genetic factors are involved. Although the molecular mechanisms involved in NAFLD onset and progression are not completely understood, the gut microbiome (GM) is thought to play a key role in the process, influencing multiple physiological functions. GM alterations in diversity and composition directly impact disease states with an inflammatory course, such as non-alcoholic steatohepatitis (NASH). However, how the GM influences liver disease susceptibility is largely unknown. Similarly, the impact of strategies targeting the GM for the treatment of NASH remains to be evaluated. This review provides a broad insight into the role of gut microbiota in NASH pathogenesis, as a diagnostic tool, and as a therapeutic target in this liver disease. We highlight the idea that the balance in metabolic fermentations can be key in maintaining liver homeostasis. We propose that an overabundance of alcohol-fermentation pathways in the GM may outcompete healthier, acid-producing members of the microbiota. In this way, GM ecology may precipitate a self-sustaining vicious cycle, boosting liver disease progression.

Download Full-text